CN-119775357-B - Anti-fatigue polypeptide in yak blood, screening method and application thereof

Abstract

The invention belongs to the technical field of polypeptide histology, and particularly relates to an anti-fatigue polypeptide in yak blood, a screening method and application thereof, wherein the anti-fatigue product is a health product or a medicine, and the screening method of the anti-fatigue polypeptide comprises the steps of carrying out sequence identification on an extracted wild blood yak blood polypeptide mixture; the polypeptide sequence with higher identification score is screened for functional polypeptide sequence, the screened polypeptide sequence is synthesized into a target polypeptide sequence by adopting a biochemical method and detected, and the synthesized polypeptide is subjected to antioxidation detection and anti-fatigue function verification on the polypeptide KD-8, so that the polypeptide KD-8 provided by the invention has obvious anti-fatigue effect.

Inventors

• SHI JUNLING
• WANG CONGCONG
• YIN DACHUAN

Assignees

• 西北工业大学

Dates

Publication Date

20260512

Application Date

20250305

Claims (1)

1. 1. The application of the polypeptide extracted from the yak blood in preparing the anti-fatigue product is characterized in that the anti-fatigue product is a health product and a medicine, the polypeptide is polypeptide KD-8, and the amino acid sequence of the polypeptide is shown as SEQ ID NO. 1.

Description

Anti-fatigue polypeptide in yak blood, screening method and application thereof Technical Field The invention belongs to the technical field of polypeptide histology, and particularly relates to an anti-fatigue polypeptide in yak blood, and a screening method and application thereof. Background Peptides are compounds formed by joining together alpha-amino acids in peptide chains, which are also proteolytic intermediates. All endogenous polypeptide components in an organism, including polypeptides produced by protein degradation or by non-coding regions, are typically below 5kDa in molecular weight. Part of the polypeptides (active peptides) play an important role in the growth and metabolism of organisms, such as semaglutin, endorphin with analgesic effect for the treatment of type 2 diabetes, etc. Partial peptides also have a taste-imparting effect, such as umami peptides and the like. However, there is no progress in the anti-fatigue polypeptide KD-8 and its related application. Disclosure of Invention Aiming at the defects in the prior art, the invention provides a polypeptide extracted from yak blood, which is specifically polypeptide KD-8, and the amino acid sequence of the polypeptide is shown as SEQ ID NO. 1. The invention also provides application of the polypeptide extracted from the yak blood in preparing an anti-fatigue product, and the anti-fatigue product is particularly a health-care product and a medicine. The invention also provides a screening method of the anti-fatigue polypeptide in the yak blood, which comprises the following steps: S1, carrying out sequence identification on an extracted wild blood yak blood polypeptide mixture; S2, screening the polypeptide sequences with higher identification scores in the step S1 for functional polypeptide sequences; S3, synthesizing a target polypeptide sequence from the polypeptide sequence screened in the step S2 by adopting a biochemical method, and detecting, wherein the target polypeptide sequence comprises the polypeptide KD-8 as set forth in claim 1, and the amino acid sequence of the polypeptide KD-8 is shown as SEQ ID NO. 1. Further, in step S3, the target polypeptide sequence is specifically polypeptide KD-8, the amino acid sequence of which is shown as SEQ ID NO.1, polypeptide PD-11, the amino acid sequence of which is shown as SEQ ID NO.2, polypeptide LG-24, the amino acid sequence of which is shown as SEQ ID NO.3, and polypeptide LK-23, the amino acid sequence of which is shown as SEQ ID NO. 4. Further, the sequence identification in step S1 is achieved by subjecting the polypeptide mixture to reductive alkylation, desalting, and liquid chromatography-tandem mass spectrometry. Further, the functional polypeptide sequence screening process in step S2 includes the steps of firstly carrying out significance scoring and sequencing on the polypeptide sequences with higher identification scores in step S1, then selecting the polypeptide sequences with higher significance scoring, calculating antioxidant amino acid ratios of the polypeptide sequences, sequencing, and querying the selected polypeptide sequences in a database for effective functional polypeptide sequences. Further, in step S3, the chemical synthesis adopts liquid phase polypeptide synthesis and solid phase polypeptide synthesis, the antioxidant activity of the synthesized polypeptide KD-8, polypeptide PD-11, polypeptide LG-24 and polypeptide LK-23 is detected and sequenced, and then the polypeptide sequence with stronger antioxidant activity is selected for the in vivo anti-fatigue function verification of the mice. Further, the antioxidant activity detection is detected by DPPH antioxidant experiments, wherein the antioxidant effect is sequentially from strong to weak, namely polypeptide LK-23, polypeptide KD-8, polypeptide LG-24 and polypeptide PD-11. Compared with the prior art, the invention has the following beneficial technical effects: The polypeptide KD-8 sequence provided by the invention is derived from yak blood, has the functions of resisting oxidation, resisting fatigue and the like, and has a plurality of potential application scenes, including but not limited to application in the aspects of medicines or health care products. Drawings Fig. 1 is a comparison graph of weight gain of mice in the anti-fatigue function verification of the polypeptide mixture provided in the embodiment 2 of the present invention, wherein (a) is a graph of weight fluctuation trend, and (b) is a graph of weight gain rate change. FIG. 2 is a graph showing evaluation of fatigue resistance index of mice in fatigue resistance verification of a polypeptide mixture according to example 2 of the present invention, wherein (a) shows swimming exhaustion time, (b) shows blood lactic acid content, (c) shows serum urea nitrogen, (d) shows liver glycogen content, (e) shows myoglycogen content, and symbol'"Indicates statistically significant difference from the control group (CK), and" ns "indicates no